Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
<br><br>Serotonin and norepinephrine reuptake inhibitors (SNRIs) work in a similar way to SSRIs except that they inhibit the reuptake of both norepinephrine and serotonin. The first SNRI was FDA-approved in December 1993.
<br><br>Increasing norepinephrine levels in tandem to serotonin levels can be particularly useful or people with psychomotor retardation (the slowing of physical movement and thought).
<br><br>Examples of SNRIs include:
<ul>
<ul><li>Effexor (venlafaxine)</li><li>Cymbalta (duloxetine)</li><li>Pristiq (desvenlafaxine)</li><li>Savella (milnacipran)</li><li>Fetzima (levomilnacipran)
</li></ul>




</ul>
Common side effects of SNRIs include nausea, drowsiness, fatigue, constipation, and dry mouth.
<br><br>Some SNRIs, like Cymbalta, can also be used to treat chronic pain, a condition closely linked to the development of depression. They have also proven useful in treating generalized anxiety, post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), panic disorder, and nerve pain associated with fibromyalgia.
<br><br>If the frontal lobe has regular frequency alpha seen in excess, especially with eyes-closed frontal alpha hypercoherence, then in our experience, an SSRI or an SNRI may be used to increase frontal function.